WebApr 11, 2024 · BTAI has been the topic of several research reports. The Goldman Sachs Group raised their price target on shares of BioXcel Therapeutics from $16.00 to $26.00 and gave the company a “neutral ... WebBTAI has a higher average analyst price target than 2939.86% of stocks in the small market cap category. In the context of stocks in the small market cap category, BIOXCEL …
BTAI Price Target, Analyst Ratings and Predictions
WebBioXcel Therapeutics (NASDAQ:BTAI) had a huge reversal on big volume Thursday, popping 1.95, or 81%, to 4.36, on 2.7 million shares and closed at the upper end of the... BioXcel Therapeutics... WebApr 12, 2024 · The latest price target for BioXcel Therapeutics ( NASDAQ: BTAI) was reported by Jefferies on March 10, 2024. The analyst firm set a price target for $22.00 … trower and trower
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Receives Consensus ...
WebApr 6, 2024 · The price target raised to $80 per share is four times as large as the last closing price. BXCL501, the treatment identified as Igalmi after its FDA approval, is … WebThe analyst firm set a price target for 66.00 expecting BTAI to rise to within 12 months (a possible 282.17% upside). 16 analyst firms have reported ratings in the last year. WebApr 10, 2024 · Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $50.00. BioXCel Therapeutics (NASDAQ:BTAI) A Hot Buy That Confuses Analysts trower and hamlins london